Entera Bio (NASDAQ:ENTX) Issues Quarterly Earnings Results, Misses Estimates By $0.06 EPS

Entera Bio (NASDAQ:ENTX) posted its quarterly earnings data on Friday. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.06), Zacks reports.

Entera Bio Trading Up 1.8%

Shares of NASDAQ ENTX opened at $2.87 on Friday. Entera Bio has a 12-month low of $0.91 and a 12-month high of $4.20. The company has a market cap of $141.46 million, a price-to-earnings ratio of -8.20 and a beta of 1.38. The stock’s 50 day simple moving average is $1.85 and its 200 day simple moving average is $1.49.

Institutional Trading of Entera Bio

Large investors have recently added to or reduced their stakes in the business. Superstring Capital Management LP acquired a new position in Entera Bio during the 4th quarter valued at about $33,000. Schonfeld Strategic Advisors LLC lifted its holdings in shares of Entera Bio by 5.2% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 596,585 shares of the company’s stock valued at $1,157,000 after purchasing an additional 29,629 shares during the last quarter. Jane Street Group LLC lifted its stake in Entera Bio by 142.6% during the fourth quarter. Jane Street Group LLC now owns 74,064 shares of the company’s stock valued at $144,000 after buying an additional 43,536 shares in the last quarter. Renaissance Technologies LLC boosted its stake in Entera Bio by 22.2% in the 4th quarter. Renaissance Technologies LLC now owns 108,001 shares of the company’s stock worth $210,000 after purchasing an additional 19,601 shares during the period. Finally, HighTower Advisors LLC boosted its position in shares of Entera Bio by 137.8% in the fourth quarter. HighTower Advisors LLC now owns 43,140 shares of the company’s stock worth $84,000 after buying an additional 25,000 shares during the period. 14.11% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on ENTX shares. Wall Street Zen raised Entera Bio to a “sell” rating in a research report on Saturday. HC Wainwright restated a “buy” rating on shares of Entera Bio in a research note on Wednesday, June 24th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Entera Bio in a research note on Friday, July 17th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Entera Bio presently has a consensus rating of “Hold” and an average target price of $9.00.

Entera Bio Company Profile

Entera Bio, Inc is a clinical‐stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations.

The company’s lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis.